New Study Finds Home Hemodialysis Patient Survival Rates Nearly Double Those of Peritoneal Dialysis

LAWRENCE, Mass., June 18, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM) is encouraging patients to take control of their dialysis therapy and consider home hemodialysis in the wake of a new study that found patient survivability rates are significantly higher with home hemodialysis (HHD) than peritoneal dialysis (PD). The Incident Cohort Study, the first of its size, was completed by the Australian and New Zealand Dialysis and Transplantation Registry and shows that the five-year survival rate for HHD is at 85 percent while the survival rate for PD patients is just 44 percent. A leading manufacturer of dialysis products, NxStage, believes the recent findings should inspire dialysis patients to ask their healthcare providers about home hemodialysis therapy with the System One. Currently, less than two percent of dialysis patients in the U.S. are performing HHD, versus approximately 9% performing PD.

"These data clearly show that excellent long-term survival can be achieved in patients that are prescribed home hemodialysis within 90 days of starting maintenance dialysis," said Dr. Eric Weinhandl, epidemiologist and lead investigator on multiple published studies on home dialysis clinical outcomes as part of the Chronic Disease Research Group. "Interestingly, the survival advantage of HHD over PD was evident in multiple frames, including younger and older patients, non-diabetics and diabetics, and early and late follow-up."

Historically, studies comparing clinical outcomes between peritoneal dialysis and home hemodialysis have been limited. The Incident Cohort Study was the largest of its kind and assessed all Australian and New Zealand adult patients receiving home dialysis on day 90 after initiation of renal replacement therapy between 2000 and 2012. It included 10,710 patients on incident peritoneal dialysis and 706 patients on incident home hemodialysis and found that the risk of death-censored technique failure for HHD was 66 percent lower than PD. Directionally, these results were very consistent with  recent presentations of survival and technique survival on NxStage HHD patients vs. PD in the US published by Weinhandl at the 2014 ASN Renal Week and 2015 NKC Spring Clinical Meeting.

"This strong clinical data backs the efficacy of HHD and affirms the results of recent studies," said NxStage President, Joe Turk. "These results further reinforce the need for clinicians to consider HHD as a first strategy for incident patients, not just when PD fails."

To learn more about NxStage and the System One, please visit NxStage.com.

Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. http://www.nxstage.com/.

About NxStage Medical
NxStage Medical Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements 
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2015. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media contact:  
Kristen K. Sheppard, Esq. 
[email protected] 
Tel: (978) 332-5923

Logo - http://photos.prnewswire.com/prnh/20110503/MM94799LOGO

SOURCE NxStage Medical, Inc.

Related Links

http://www.nxstage.com